As the White House mulls a pick to lead the FDA, the Trump ad­min­is­tra­tion has been wash­ing away the mark of for­mer com­mis­sion­er Mar­ty Makary...

Richard Paz­dur, who spent more than two decades lead­ing the FDA’s can­cer drug re­views, said the agency has a “gold­en op­por­tu­ni­ty” to re­struc­ture af­ter be­ing...

GSK's $10.6 bil­lion ac­qui­si­tion of Nu­va­lent is de­liv­er­ing sur­pris­ing­ly ear­ly re­sults.

The FDA on Wednes­day ap­proved one of Nu­va­len­t's lung can­cer med­i­cines two months ear­li­er than...

Pres­i­dent Don­ald Trump on Tues­day evening said he will im­pose up to 200% tar­iffs on gener­ic drugs sold in the US, if com­pa­nies do not man­u­fac­ture...

Ar­row­head Phar­ma­ceu­ti­cals’ lipid-low­er­ing drug has hit in two late-stage tri­als that could ex­pand its use in­to a much wider pop­u­la­tion.

Da­ta shared Wednes­dayshowed that...

To gain con­trol of Cri­net­ics Phar­ma­ceu­ti­cals, Ver­tex Phar­ma­ceu­ti­cals was will­ing to pay the sec­ond-high­est pre­mi­um so far in bio­phar­ma's ban­ner year for M&A. And the Boston...